Investigating new ways to kill cancer cells without triggering apoptosis
Lysosomal-mitochondrial signaling in non-apoptotic cancer cell death
This study is looking at a new way to help fight cancer by using a special compound called HMA that can kill stubborn cancer cells while leaving healthy cells alone, and it's for anyone interested in better treatments for cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10977348 on NIH RePORTER |
What this research studies
This research focuses on developing a novel approach to eliminate cancer cells that resist traditional treatments by targeting different cell death mechanisms. The study explores how lysosomal and mitochondrial signaling can induce a specific type of cell death in cancer cells, using a compound called hexamethylene amiloride (HMA). HMA has shown promise in killing various cancer cell types while sparing normal cells, making it a potential breakthrough in cancer therapy. The research aims to understand the underlying processes that allow HMA to effectively target and destroy cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with therapy-resistant cancers, particularly those who have not responded to standard chemotherapy.
Not a fit: Patients with early-stage cancers that are effectively managed with conventional treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer patients who do not respond to conventional therapies.
How similar studies have performed: Other research has indicated that targeting non-apoptotic cell death pathways can be effective, suggesting this approach may hold promise.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Carraway, Kermit L — University of California at Davis
- Study coordinator: Carraway, Kermit L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.